Zdrowie i gospodarka · 30/04/2015

FDA Releases Guidance on Demonstrating Biosimilarity to Reference Products

The Food and Drug Administration (FDA) has released a guidance document titled "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product" to help pharmaceutical companies prove that their biosimilar products are comparable to existing reference products, facilitating the approval process through an accelerated licensure pathway.